Did you mean to say Factor XI, or was that a typo? T.i.a."
No typo.
ISIS-FXIRx
"ISIS-FXIRx is an antisense drug designed to treat clotting disorders. It targets Factor XI, a clotting factor produced in the liver. High levels of Factor XI are linked to heart attack, stroke and blood clots. In preclinical studies, ISIS-FXIRx demonstrated potent antithrombotic activity and a superior safety profile (lower risk of bleeding) compared with standard anti-clotting agents, including low molecular weight heparin, warfarin and Factor Xa inhibitors. We plan to begin IND-enabling studies on ISIS-FXIRx in the first half of 2010."
ISIS has started to give some details about FXIR in their presentations if your interested. Pretty interesting & ISIS will be looking for big partnership dollars in a few years.
This is the first antisense aimed at a clotting factor, but they have a second one they'll be bringing into Phase I next year. Not much has been detailed on the second target.
Market Data 
Markets 
AI
